当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy.

Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy.

Abstract：

:We retrospectively studied a series of 23 patients (median age 50 years, range 29-59 years) with multiple myeloma (MM), treated in first relapse by a sequential autologous-allogeneic tandem approach. Tandem transplantation (TT) consisted in high dose melphalan (HDT) and auto-SCT followed by an (allo-SCT) preceded by two gray TBI non-myeloablative conditioning. All patients received a first HDT as frontline treatment. At day 100 post allo-SCT, complete donor chimerism was detected in 22 patients (95%). Acute GVHD was observed in 19 patients (15 grade I-II (65%) and 4 grade III-IV (17%)). Ten patients (43%) developed an extensive chronic GVHD. The non-relapse mortality at 1 year was 17%. After TT, the overall response rate was 91% (17% partial response, 35% very good partial remission and 39% complete remission). At 2 years, OS was 61%. Median event-free survival and OS were 36.8 and 60 months, respectively. Based on the propensity score matching method, a significant survival advantage could be seen in patients treated with TT as compared with non-allografted patients. Thus, allo-SCT, in TT approach, provides a high response rate with low toxicity and may improve survival of patients with relapsing MM.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Karlin L,Arnulf B,Chevret S,Ades L,Robin M,De Latour RP,Malphettes M,Kabbara N,Asli B,Rocha V,Fermand JP,Socie G

doi

10.1038/bmt.2010.90

subject

Has Abstract

pub_date

2011-02-01 00:00:00

pages

250-6

issue

2

eissn

0268-3369

issn

1476-5365

pii

bmt201090

journal_volume

46

pub_type

杂志文章

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Transplantation of highly purified HLA-identical sibling donor peripheral blood CD34+ cells without prophylactic post-transplant immunosuppression in adult patients with first chronic phase chronic myeloid leukemia: results of a phase II study.

    abstract：:The feasibility of transplantation using highly purified G-CSF-mobilized peripheral blood CD34+ cells from HLA-identical sibling donors without prophylactic post-transplant immunosuppression was prospectively studied in 10 adult first chronic phase chronic myeloid leukemia (CML) patients with special reference to graf...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1702635

    authors： Beelen DW,Peceny R,Elmaagacli A,Ottinger H,Kummer G,Opalka B,Seeber S,Schaefer UW

    更新日期：2000-10-01 00:00:00

  • Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.

    abstract：:Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds the Flt3 (CD135) receptor expressed on hematopoietic stem cells (HSCs), early progenitor cells, immature thymocytes and steady-state dendritic cells (DCs) and induces their proliferation, differentiation, development and mobilization in the bone marrow, peripher...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2015.74

    authors： Anandasabapathy N,Breton G,Hurley A,Caskey M,Trumpfheller C,Sarma P,Pring J,Pack M,Buckley N,Matei I,Lyden D,Green J,Hawthorne T,Marsh HC,Yellin M,Davis T,Keler T,Schlesinger SJ

    更新日期：2015-07-01 00:00:00

  • Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin.

    abstract：:Autologous bone marrow transplantation may contribute to the treatment of several types of lymphoreticular malignancies. Recent studies have suggested that a combination of chemoseparation and immunoseparation may be more effective than either modality alone in eliminating malignant cells from human bone marrow. In th...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Montgomery RB,Kurtzberg J,Rhinehardt-Clark A,Haleen A,Ramakrishnan S,Olsen GA,Peters WP,Smith CA,Haynes BF,Houston LL

    更新日期：1990-06-01 00:00:00

  • Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow.

    abstract：:A retrospective comparison was carried out on adult patients receiving HLA-identical allogeneic haemopoietic stem cell transplants from siblings in Australia in 1996, comparing bone marrow with G-CSF-mobilised peripheral blood stem cells. A total of 131 transplant recipients from nine centres were included in this stu...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1703088

    authors： Nivison-Smith I,Bradstock KF,Szer J,Durrant S,Dodds A,Hermann R,Schwarer AP,Gibson J,To LB,Arthur C,Australian Bone Marrow Transplant Cooperative Sutdy Group.

    更新日期：2001-07-01 00:00:00

  • Treatment of refractory lymphoma with high dose cytarabine, cyclophosphamide and either TBI or VP-16 followed by autologous bone marrow transplantation.

    abstract：:This study was designed to test the efficacy and toxicity of combining high-dose cytarabine (3 g/m2 every 12 h x 8 doses day -7 to day -4, total dose 24 g/m2), methyl prednisolone (0.5 mg/kg every 4 h day -7 to day -1), and cyclophosphamide (CY) (60 mg/kg day -3 and day -2) with either total body irradiation (TBI) (90...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Broun ER,Tricot G,Akard L,Nichols C,Cheerva A,Jansen J

    更新日期：1990-05-01 00:00:00

  • The EBMT activity survey 2008: impact of team size, team density and new trends.

    abstract：:Six hundred and fifteen centers from 45 countries reported a total 30,293 HSCT to this 2008 EBMT survey with 26,810 first transplants (40% allogeneic, 60% autologous). This corresponds to an increase of 7% for the allogeneic and 3% for the autologous HSCT. Main indications were leukemias (32%; 89% allogeneic); lymphom...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2010.69

    authors： Gratwohl A,Baldomero H,Schwendener A,Gratwohl M,Apperley J,Frauendorfer K,Niederwieser D

    更新日期：2011-02-01 00:00:00

  • Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant.

    abstract：:The purpose of this study was to evaluate pre-transplant T-cell status in autologous hematopoietic progenitor-cell transplantation (HPCT) recipients. Between 1999 and 2002 we prospectively enrolled 85 autologous HPCT recipients with solid tumors (N = 50) or hematological malignancies (n = 35). Patient diagnoses includ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1705073

    authors： Rosinski SL,McNiece IK,Shpall EJ,Clough N,Russell P,Blunk B,Nieto Y

    更新日期：2005-09-01 00:00:00

  • Elevated soluble human leukocyte antigen G levels in patients after allogeneic stem cell transplantation are associated with less severe acute and chronic graft-versus-host disease.

    abstract：:HLA-G is a non-classical class I molecule which induces tolerance in allogeneic situations by inhibition of cytotoxic NK and CD8 + T cells and by induction of regulatory T cells. Concordantly, in solid organ transplantation HLA-G is associated with a lower risk for acute and chronic rejection, whereas its role in allo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-018-0145-1

    authors： Kordelas L,da Silva Nardi F,Wagner B,Ditschkowski M,Liebregts T,Lindemann M,Heinemann FM,Horn PA,Beelen DW,Rebmann V

    更新日期：2018-09-01 00:00:00

  • Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens.

    abstract：:We investigated the impact of the most commonly used preparative regimens on the outcome of 395 patients with diffuse large cell lymphoma (DLCL), consecutively reported to the registry of the Spanish GEL/TAMO. Among them, 139 (35%) were autografted in 1st CR, 86 (22%) in 2nd/3rd CR, 124 (31%) had chemosensitive diseas...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1702795

    authors： Salar A,Sierra J,Gandarillas M,Caballero MD,Marín J,Lahuerta JJ,García-Conde J,Arranz R,León A,Zuazu J,García-Laraña J,López-Guillermo A,Sanz MA,Grañena A,García JC,Conde E,GEL\/TAMO Spanish Cooperative Group.

    更新日期：2001-02-01 00:00:00

  • Role of marrow microenvironment in engraftment and maintenance of allogeneic hematopoietic stem cells.

    abstract：:Following allogeneic marrow transplantation a competent marrow microenvironment consists of a complex mixture of both donor and host derived cells. Clearly some forms of genetic disparity between donor and host can compromise appropriate interactions and function of these cells. The competency of the microenvironment ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Torok-Storb B,Holmberg L

    更新日期：1994-01-01 00:00:00

  • FK506-associated limbic injury following umbilical cord blood transplantation.

    abstract：:A 5-year-old girl with Ph-positive chronic myelogenous leukemia, who underwent umbilical cord blood transplantation, developed two episodes of electrical status epilepticus while receiving tacrolimus (FK506) then cyclosporin A (CsA), as treatment against graft-versus-host disease. MRI including diffusion weighted MR i...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704168

    authors： Yoshida Y,Shimada H,Mori T,Yoshihara H,Takeoka M,Takahashi T

    更新日期：2003-09-01 00:00:00

  • Allogeneic marrow transplantation in non-Hodgkin's lymphoma.

    abstract：:Nine individuals between 15 and 43 years of age with non-Hodgkin's lymphoma underwent allogeneic marrow transplantation following busulfan 16 mg/kg and cyclophosphamide 120 mg/kg. These individuals were not considered optimal candidates for autologous transplantation chiefly because of marrow involvement or resistance...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：

    authors： Copelan EA,Kapoor N,Gibbins B,Tutschka PJ

    更新日期：1990-01-01 00:00:00

  • Single and double autotransplants for relapsing/refractory Hodgkin's disease: results of two consecutive trials.

    abstract：:To evaluate a strategy of one cycle of dose-intensive chemotherapy for patients with Hodgkin's disease in sensitive relapse and two cycles for those with refractory disease, 122 patients received dose-intensive chemotherapy followed by autotransplant in two consecutive studies. Patients with refractory disease were of...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1700682

    authors： Ahmed T,Lake DE,Beer M,Feldman EJ,Preti RA,Seiter K,Helson L,Mittelman A,Kancherla R,Ascensao J,Akhtar T,Cook P,Goldberg R,Coleman M

    更新日期：1997-03-01 00:00:00

  • Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation.

    abstract：:Infectious complications are frequent events in patients undergoing high-dose cytotoxic chemotherapy with subsequent autologous peripheral blood stem cell transplantation (PBSCT). To evaluate whether a single subcutaneous injection of pegfilgrastim (6 mg) is as safe and effective as daily filgrastim (5 mug/kg/day), 60...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704927

    authors： Staber PB,Holub R,Linkesch W,Schmidt H,Neumeister P

    更新日期：2005-05-01 00:00:00

  • Syngeneic peripheral blood stem cell transplantation with brief immunosuppression for severe aplastic anemia.

    abstract：:We report the cases of two severe aplastic anemia (SAA) patients who were successfully treated with syngeneic peripheral blood stem cell transplantation (PBSCT) using immunosuppression without high-dose chemotherapy or irradiation for conditioning. A 21-year-old woman with SAA of 6 years duration had been transfused h...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702150

    authors： Hwang WL,Yang Y,Chen GR,Tsai CS,Jour JH

    更新日期：2000-02-01 00:00:00

  • Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry.

    abstract：:A questionnaire comprised of a series of clinical vignettes illustrating potential difficulties in diagnosis, grading and treatment of chronic graft-versus-host disease (GVHD) was completed by 65 bone marrow transplant physicians from 51 transplant centers worldwide. The concordance index (CI) for responses to each qu...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Atkinson K,Horowitz MM,Gale RP,Lee MB,Rimm AA,Bortin MM

    更新日期：1989-05-01 00:00:00

  • Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.

    abstract：:As low trough levels of mycophenolic acid (MPA) have been measured in recipients of allo-SCTs, we performed a pilot study targeting mycophenolate mofetil (MMF) doses according to the MPA area under the concentration (AUC) levels. Twenty-nine patients were transplanted from matched sibling (n=7) and unrelated donors (n...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.85

    authors： Haentzschel I,Freiberg-Richter J,Platzbecker U,Kiani A,Schetelig J,Illmer T,Ehninger G,Schleyer E,Bornhäuser M

    更新日期：2008-07-01 00:00:00

  • Allogeneic stem cell transplantation for Fanconi Anaemia. Severe Aplastic Anaemia Working Party of the EBMT and EUFAR. European Group for Blood and Marrow Transplantation.

    abstract：:Fanconi anaemia is a hereditary disorder characterised by chromosomal breaks increased by cross-linking agents. Bone marrow transplantation is the treatment of choice when a HLA identical sibling donor has been identified. The use of low-dose cyclophosphamide with thoraco-abdominal irradiation for the conditioning reg...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Guardiola P,Socié G,Pasquini R,Dokal I,Ortega JJ,van Weel-Sipman M,Marsh J,Locatelli F,Souillet G,Cahn JY,Ljungman P,Miniero R,Shaw J,Vermylen C,Archimbaud E,Bekassy AN,Krivan G,Di Bartolomeo P,Bacigalupo A,Gluckman

    更新日期：1998-04-01 00:00:00

  • GI complications in pediatric patients post-BMT.

    abstract：:This retrospective study comprehensively examined hepatic and gastrointestinal complications post-bone marrow transplant (BMT) in a heterogeneous group of 132 pediatric patients that underwent 142 transplants. Hyperbilirubinemia occurred in 28% of this population with clinically evident jaundice in 16%. Acute graft-ve...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705004

    authors： Barker CC,Anderson RA,Sauve RS,Butzner JD

    更新日期：2005-07-01 00:00:00

  • The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.

    abstract：:In this multicenter study, we assessed the use of palifermin (recombinant human-keratinocyte growth factor 1) in the prevention of oral mucositis (OM) and acute GvHD (aGvHD) induced by a hematopoietic stem cell transplant (HSCT). Fifty-three patients with hematological diseases received three doses of palifermin (60 m...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1705846

    authors： Nasilowska-Adamska B,Rzepecki P,Manko J,Czyz A,Markiewicz M,Federowicz I,Tomaszewska A,Piatkowska-Jakubas B,Wrzesien-Kus A,Bieniaszewska M,Duda D,Szydlo R,Halaburda K,Szczepinski A,Lange A,Hellman A,Robak T,Skotnicki A

    更新日期：2007-11-01 00:00:00

  • Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation.

    abstract：:Although neurocognitive impairment has been established as a major issue among cancer survivors, the real-world consequences of this impairment are unclear. This study investigated the relationship between neurocognitive functioning and medication management ability over time among 58 patients treated with allogeneic ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2016.2

    authors： Mayo S,Messner HA,Rourke SB,Howell D,Victor JC,Kuruvilla J,Lipton JH,Gupta V,Kim DD,Piescic C,Breen D,Lambie A,Loach D,Michelis FV,Alam N,Uhm J,McGillis L,Metcalfe K

    更新日期：2016-06-01 00:00:00

  • Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.

    abstract：:Survival for high-risk neuroblastoma patients is still suboptimal. Although stem cell transplantation (SCT) is used, there is no consensus as to which conditioning regimen has the greatest efficacy and fewest toxicities. We assessed the incidence of and risk for hepatic veno-occlusive disease (VOD) for neuroblastoma p...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-018-0298-y

    authors： Schechter T,Perez-Albuerne E,Lin TF,Irwin MS,Essa M,Desai AV,Frangoul H,Yanik G,Dupuis LL,Jacobsohn D,Kletzel M,Ranalli M,Soni S,Seif AE,Grupp S,Dvorak CC

    更新日期：2020-03-01 00:00:00

  • High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB).

    abstract：:A retrospective analysis of data from the European Rhabdoid Registry (EU-RHAB) was performed to describe the outcome of children with atypical teratoid/rhabdoid tumors (AT/RT) who underwent high-dose chemotherapy (HDCT) with auto-SCT. Nineteen patients (male, n=15; median age at diagnosis 21 months) were identified. N...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2013.208

    authors： Benesch M,Bartelheim K,Fleischhack G,Gruhn B,Schlegel PG,Witt O,Stachel KD,Hauch H,Urban C,Quehenberger F,Massimino M,Pietsch T,Hasselblatt M,Giangaspero F,Kordes U,Schneppenheim R,Hauser P,Klingebiel T,Frühwald MC

    更新日期：2014-03-01 00:00:00

  • Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen.

    abstract：:In an attempt to reduce the incidence of chronic GVHD (cGVHD) after reduced-intensity conditioning (RIC), we used BM instead of PBSC and added melphalan 100 mg/m(2) to the classical association of fludarabine, 30 mg/m(2)/day for 3 days and TBI, 200 cGy (FLUIM regimen). Between 2000 and 2012, 51 patients received BM wi...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2014.193

    authors： Gomez E,Duléry R,Langlois C,Coiteux V,Terriou L,Magro L,Gauthier J,de Berranger E,Duhamel A,Yakoub-Agha I

    更新日期：2014-12-01 00:00:00

  • Successful outcomes of second hematopoietic stem cell transplantation with total nodal irradiation and ATG conditioning for graft failure in adult patients with severe aplastic anemia.

    abstract：:Data regarding the optimal approach for second allogeneic hematopoietic stem cell transplantation (HSCT) after graft failure (GF) in acquired severe aplastic anemia (SAA) are still limited and heterogeneous. We examined 24 patients who underwent second HLA-matched sibling donor (MSD) peripheral blood HSCT for GF. The ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/s41409-018-0154-0

    authors： Yahng SA,Park SS,Jeon YW,Yoon JH,Shin SH,Lee SE,Cho BS,Eom KS,Kim YJ,Lee S,Min CK,Kim HJ,Cho SG,Kim DW,Min WS,Lee JW

    更新日期：2018-10-01 00:00:00

  • Complete heart block in association with graft-versus-host disease.

    abstract：:An infant who received haploidentical BM for severe combined immunodeficiency (SCID) developed acute, reversible complete heart block in association with an exacerbation of GVHD. Respiratory distress and myocardial dysfunction were also seen with this and previous GVHD exacerbations. The patient had not received chemo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701038

    authors： Gilman AL,Kooy NW,Atkins DL,Ballas Z,Rumelhart S,Holida M,Lee N,Goldman F

    更新日期：1998-01-01 00:00:00

  • Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT.

    abstract：:In this cross-sectional study, we compared the quality of life (QOL) in transfusion-dependent thalassemic patients who survived matched sibling hematopoietic SCT (HSCT, n=24) with patients treated conventionally with transfusion and iron chelation (n=74). WHOQOL-BREF(HK) and PedsQL questionnaires were administered to ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/bmt.2008.165

    authors： Cheuk DK,Mok AS,Lee AC,Chiang AK,Ha SY,Lau YL,Chan GC

    更新日期：2008-09-01 00:00:00

  • Absence of IL-23p19 in donor allogeneic cells reduces mortality from acute GVHD.

    abstract：:The p19 dimer of interleukin 23 (IL-23) has been reported to have a major role in the pathogenesis of many experimental and clinical autoimmune diseases and may also have a prominent role in transplantation. We reasoned that deficiency of p19 in the allogeneic donor transplant might reduce the inflammation caused by a...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2009.215

    authors： Thompson JS,Chu Y,Glass JF,Brown SA

    更新日期：2010-04-01 00:00:00

  • Rapid helper T-cell recovery above 200 x 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation.

    abstract：:The current study evaluates the role of quantitative measurement of peripheral lymphocyte subsets, especially CD4+ helper T-cell recovery, in predicting transplant outcomes including overall survival (OS) and non-relapse mortality (NRM) after allogeneic stem cell transplantation. A total of 69 allogeneic recipients we...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705381

    authors： Kim DH,Sohn SK,Won DI,Lee NY,Suh JS,Lee KB

    更新日期：2006-06-01 00:00:00

  • Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.

    abstract：:Trial outcomes comparing cytokine agents for PBSC mobilization in autologous hematopoietic transplant patients have been controversial. We performed a systematic review and meta-analysis of evidence available on pegfilgrastim vs filgrastim in chemo-cytokine mobilization. Electronic literature searches of PubMed, EMBAS...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,meta分析,评审

    doi：10.1038/bmt.2014.297

    authors： Kim MG,Han N,Lee EK,Kim T

    更新日期：2015-04-01 00:00:00